Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00154271
Status:
COMPLETED
Last Update Posted:
2011-11-08
First Post:
2005-09-08
Brief Title:
Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein hsCRP
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein hsCRP
Status:
COMPLETED
Status Verified Date:
2006-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study compares the efficacy of an aggressive versus a moderate initial antihypertensive regimen to reduce blood pressure in patients with Stage 2 hypertension Additionally the study examines the effects of blood pressure reduction on the levels of high sensitivity hsCRP Although the main goal is to determine the overall effect of blood pressure reduction on hsCRP levels analysis will also evaluate whether an aggressive antihypertensive regimen is more effective than a moderate one in reducing hsCRP levels
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None